A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This study will determine the maximum tolerated dose of oral ixabepilone administered for 5
successive days every 21 days in participants with advanced cancer. The safety, tolerability,
and pharmacokinetics of ixabepilone in the body will be studied. In addition, this study will
assess preliminary evidence of the effect of food and famotidine on the pharmacokinetics of
oral ixabepilone.